Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 18/20 | 0.63 |
| ▸ | MAOA | P21397 | 17/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28689930 | 0.80 | MAOB (0.74) | MAOBMAOAKDM4EMEN1MAPT | |
| SCHEMBL18998987 | 0.78 | MAOA (1.00) | MAOBMAOA | |
| SCHEMBL17144586 | 0.78 | MAOA (1.00) | MAOBMAOA | |
| SCHEMBL19017688 | 0.77 | MAOA (1.00) | MAOBMAOA | |
| SCHEMBL17150990 | 0.77 | MAOA (1.00) | MAOBMAOA | |
| Bromide SCHEMBL29420161 | 0.77 | MAOA (0.97) | MAOBMAOA | |
| SCHEMBL17150982 | 0.76 | MAOA (0.74) | MAOBMAOA | |
| SCHEMBL1916014 | 0.76 | KMT2A (0.51) | KDM4EMEN1MAPTKMT2AMAPK1 | |
| SCHEMBL17150981 | 0.70 | MAOA (0.76) | MAOBMAOAALDH1A1 | |
| SCHEMBL17144584 | 0.70 | MAOA (1.00) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| WO-2015150824-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | LMNB2, LMNB1, LMNA | MAOB 4229/4885MAOA 4114/4885KDM4E 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.